Tafamidis Reduced the Decline in Health-Related Quality of Life in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT)

Journal of Cardiac Failure - United States
doi 10.1016/j.cardfail.2019.07.024
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Extrapolation of Data From the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) Further Highlights the Survival Benefit of Tafamidis in Transthyretin Amyloid Cardiomyopathy

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

Tafamidis for Autonomic Neuropathy in Hereditary Transthyretin (ATTR) Amyloidosis: A Review

Clinical Autonomic Research
MedicineEndocrineNeurologyAutonomic Systems
2019English

Personalized Medicine Approach for Optimizing the Dose of Tafamidis to Potentially Ameliorate Wild-Type Transthyretin Amyloidosis (Cardiomyopathy)

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Internal MedicineMedicine
2015English

A Comprehensive Safety Profile of Tafamidis in Patients With Transthyretin Amyloid Polyneuropathy

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Internal MedicineMedicine
2019English

Cardiac Findings and Events Observed in an Open-Label Clinical Trial of Tafamidis in Patients With Non-Val30Met and Non-Val122Ile Hereditary Transthyretin Amyloidosis

Journal of Cardiovascular Translational Research
GeneticsPharmaceutical ScienceCardiovascular MedicineMolecular MedicineCardiology
2015English

Positive Real-World Effectiveness of Tafamidis for Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2015English

Transthyretin Familial Amyloid Polyneuropathy Impact on Health-Related Quality of Life

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2015English

Hereditary ATTR Amyloidosis With Cardiomyopathy Caused by the Novel Variant Transthyretin Y114S (p.Y134S)

Internal Medicine
Internal MedicineMedicine
2019English

CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis

Canadian Journal of Cardiology
Cardiovascular MedicineCardiology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy